Arvinas, Inc. (ARVN): Price and Financial Metrics
ARVN Price/Volume Stats
| Current price | $6.92 | 52-week high | $34.11 |
| Prev. close | $6.95 | 52-week low | $5.90 |
| Day low | $6.70 | Volume | 1,990,100 |
| Day high | $7.06 | Avg. volume | 2,264,184 |
| 50-day MA | $7.32 | Dividend yield | N/A |
| 200-day MA | $17.93 | Market Cap | 505.10M |
ARVN Stock Price Chart Interactive Chart >
Arvinas, Inc. (ARVN) Company Bio
Arvinas Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.
ARVN Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ARVN Price Returns
| 1-mo | 3.75% |
| 3-mo | -62.14% |
| 6-mo | -73.30% |
| 1-year | -75.02% |
| 3-year | -84.56% |
| 5-year | -80.55% |
| YTD | -63.90% |
| 2024 | -53.43% |
| 2023 | 20.32% |
| 2022 | -58.35% |
| 2021 | -3.29% |
| 2020 | 106.69% |